Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2005-05-03
2005-05-03
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S184100, C424S247100, C435S071300, C514S002600, C530S350000
Reexamination Certificate
active
06887476
ABSTRACT:
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
REFERENCES:
patent: 2373454 (1945-04-01), Bumy et al.
patent: 2719102 (1955-09-01), Baldwin
patent: 3132995 (1964-05-01), Berger et al.
patent: 4713240 (1987-12-01), Wilkins et al.
patent: 4832936 (1989-05-01), Dystra et al.
patent: 5053005 (1991-10-01), Borodic
patent: 5055291 (1991-10-01), Lam et al.
patent: 5055302 (1991-10-01), Laties et al.
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 9400481 (1994-01-01), None
patent: 9528171 (1995-10-01), None
Davis et al., 1993. Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A. Movement Disorder: official journal of the Movement Disorder Society, vol. 8, No. 3, p. 371, abstract only.*
Correspondence Dated Dec. 10, 1991 Between William C. Shepherd and Ira Sanders.
Correspondence Dated Apr. 13, 1992 Between Ira Sanders and Angelika S. Aswad Regarding “Animal Study”.
Partial Correspondence Dated Apr. 24, 1992 Between Angelika S. Aswad and Dr. Sanders Regarding “Botulinum Toxin to Decrease Salivary Flow”.
Ambache, J. Physiol. (1951) 113, 1-17.
Ambache, J. Physiol. (1949) 108, 127-141.
Brin; Arch. De Neurobiol. 54. Supl. 3 (7-23) 1991.
Jenzer et al; Schweiz. Med. Wschr. (1974); 104, 685-693 (w/ English translation).
Poungvarin et al; J. Med. Assoc. Thai. (Apr. 1992) 75 (4) 199-203.
Greene, Paul E., et al.;Response to Botulinum Toxin F in Seronegative Botulinum Toxin A-Resistant Patients; Movement Disorders; vol. 11, No. 2; pp. 181-184 (Mar. 1996).
Moyer, E.D., et al.;Effects of Intramuscular Injection of Botulinum Toxin Type B in Nonhuman Primates; Botulinum and Tetanus Neurotoxins—Neurotransmission and Biomedical Aspects; Bibhuti R. Dasgupta, Editor; Plenum Press (1993).
Price, J., et al.;A Comparative-Study of Tear Secretion in Blepharospasm and Hemifacial Spasm Patients Treated with Botulinum Toxin; Journal of Clinical Neuro-Ophthalmology; vol. 13, No. 1; pp. 67-71 (Mar. 1993). Abstract only.
Scott, Alan B., et al.;Systemic Toxicity of Botulinum Toxin by Intramuscular Injection in the Monkey; Movement Disorders; vol. 3, No. 4; pp. 333-335 (1988).
Truong, Daniel D., et al.;BotB(Botulinum Toxin Type B): Evaluation of Safety and Tolerability in Botulinum Toxin Type A-Resistant Cervical Dystonia Patients(Preliminary Study); Movement Disorders; vol. 12, No. 5; pp. 772-775 (Sep. 1997).
Tsui, J.K., et al.;A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis; The Canadian Journal of Neurological Sciences; vol. 12, No. 4; pp. 314-316 (Nov. 1985).
Tsui, Joseph K.C., et al.;Local Treatment of Spasmodic Torticollis with Botulinum Toxin; Le Journal Canadien des Sciences Neurologiques; vol. 14, No. 3 (Supplement); pp. 533-535 (Aug. 1987).
Med Ad News staff;Athena Makes a Wise Move; Medical Advertising News; p. 4 (Nov. 1992).
U.S. Food and Drug Administration;List of Orphan Designations and Approvals; pp. 1 and 42-46 of 275 (computer search printout dated Jan. 18, 2000).
Aoki K. Roger
Carlson Steven R.
Grayston Michael W.
Leon Judith M.
Allergan Inc.
Campell Bruce R.
Chism B. Dell
Donovan Stephen
LandOfFree
Method for treating pain with botulinum toxin type B does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating pain with botulinum toxin type B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating pain with botulinum toxin type B will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3415623